Whole genome sequencing of tumour cells could help predict the prognosis of a patient’s cancer and offer clues to identify the most effective treatment, suggests an international study published today in Nature Medicine.
Previously, it was like going on a voyage with only a limited map, but now, with whole genome sequencing we have a much better, more detailed map and know the best route to reach our destination
Our DNA, the human genome, comprises of a string of molecules known as nucleotides. These are represented by the letters A, C, G and T. Sometimes, changes occur in the ‘spelling’ of our DNA – an A becomes a G, for example. These changes, known as mutations, can be caused by a number of factors, some spontaneous, others environmental, such as exposure to tobacco smoke or to ultraviolet light, and all leave characteristic signatures on the genome.
As cells divide and multiply, they make copies of their DNA, so any spelling mistakes will be reproduced. Over time, the number of errors accumulates, leading to uncontrolled cell growth – the development of tumours.
Whole genome sequencing (WGS) is a technique that involves reading the entire genetic blueprint of a cancer cell and comparing it to a patient’s healthy cells to see how the DNA has mutated. By studying all the mutations present in a whole cancer genome and seeking all the signatures in them, it is possible to identify the various factors that have acted upon the tumour.
To understand whether WGS might be useful in a clinical setting, Cambridge researchers teamed up with colleagues in Sweden running a population-wide project called SCAN-B, which has been recruiting all women diagnosed with breast cancer in the South of Sweden since 2010. This was critical as SCAN-B has a large amount of clinical outcome data.
This international collaboration of researchers used WGS to analyse tumours from patients who had been diagnosed as having triple negative breast cancers. These cancers are so-called because they lack three key molecules known as receptors. They account for around 9% of breast cancers and are associated with poorer outcomes. They are also more common amongst women with African and Asian ancestry.
“Whole genome sequencing gives us a complete view of the cancer genome. It reveals many things that we couldn’t see previously, because we simply did not look for them,” explains Dr Serena Nik-Zainal from the Medical Research Council Cancer Unit at the University of Cambridge, who led the study.
“Having a complete cancer genome map for each patient helps us to understand what has caused each patient’s tumour and treat each individual more effectively. Previously, it was like going on a voyage with only a limited map, but now, with whole genome sequencing we have a much better, more detailed map and know the best route to reach our destination.”
The researchers then applied a machine learning algorithm called HRDetect, which they had previously developed to identify tumours with signatures caused by mutations in the BRCA1 or BRCA2 genes. Having a variant of either of these two genes greatly increases an individual’s risk of developing breast cancer and a relatively new class of anti-cancer drug called PARP-inhibitors have been developed specifically for these tumours. HRDetect scores had previously suggested that a greater proportion of women in the general population could have tumours that are very similar to BRCA1/BRCA2-mutant cancers.
Taking the scores, the team categorised each patient as either high, intermediate or low scoring.
Patients who scored highly were those that had the best outcomes using current treatments for triple negative breast cancers – they are also most likely to respond to PARP inhibitors.
Surprisingly, those with intermediate scores had the poorest outcomes. Current triple negative breast cancer treatments had limited effectiveness suggesting that new approaches would be necessary to tackle these cancers. However, the genetic changes and signatures revealed through WGS gave clues to the mechanisms driving these tumours, which in turn may help inform the development of new drugs.
Those patients with low scores also have poor outcomes, though not as badly as those in the intermediate group. However, the WGS profile in some of these tumours suggested biological abnormalities that could potentially be targeted by existing drugs or drugs currently going through clinical trials, such as so-called checkpoint inhibitors or AKT inhibitors.
“Using whole genome sequencing, we can truly discriminate tumours that may or may not respond to current drugs among triple negative breast cancer patients, a type of breast cancer that we still struggle to treat well,” says first author Dr Johan Staaf from the Department of Clinical Sciences, Lund University, Sweden.
“But importantly, this approach also gives us clues to some of the mechanisms that are going wrong in the poor-outcome tumours, and hence how we might treat those tumours differently or how we might develop new drugs.”
The speed of sequencing technology has progressed such that WGS can be carried out in 24 hours, with another 24-48 hours for analysis of the data. In theory, therefore, it should be possible to offer whole genome screening as a matter of course to all patients, allowing a personal readout of their tumour and potential treatment options.
“The potential for whole genome sequencing to open up a personalised approach to treating cancer is huge,” says Dr Nik-Zainal. “In the past, the cost and issues with managing the huge volume of data created barriers to its widespread application. But we are moving closer to a time where it can be routinely offered to all patients, with the potential to transform the management of even difficult-to-treat cancers.”
The Latest on: Whole genome sequencing
via Google News
The Latest on: Whole genome sequencing
- DNA Sequencing Market – Current Opportunities and Growth Drivers Analysison November 30, 2020 at 12:43 am
Over the years, exome sequencing and whole genome sequencing have established their role in clinical applications in population studies. A case in point is the diagnostic application of DNA sequencing ...
- Dante Labs Launches Best Ever Black Friday Offer for Whole Genomeon November 24, 2020 at 8:00 pm
Dante Labs announced today its new Black Friday - Cyber Monday offering for Whole Genome Sequencing and reports for 2020. This offering is ...
- Brazilian researchers complete Latin America’s largest whole-genome sequencing of elderly peopleon November 18, 2020 at 2:54 pm
Analysis of DNA from 1,171 over-sixties living in São Paulo will enable scientists to identify genetic mutations responsible for diseases or important to healthy aging, according to the authors of the ...
- COVID-19 Genomics UK Consortium gets £12.2 million funding to expand whole genome sequencing of SARS-CoV-2 viruson November 17, 2020 at 8:30 pm
Genomics UK Consortium gets £12.2 million funding to expand whole genome sequencing of SARS-CoV-2 virus: United Kingdom Wednesday, November 18, 2020, 10:00 Hrs [IST] The ...
- Sanger Institute & COG-UK receive £12.2M for COVID-19 genomic surveillance systemon November 16, 2020 at 8:18 am
The Department for Health and Social Care Testing Innovation Fund has backed the Wellcome Sanger Institute and the COVID-19 Genomics UK (COG-UK) Consortium in expanding whole genome sequencing of ...
- Whole Genome Sequencing Marketon November 16, 2020 at 2:37 am
Market Growth Insight has presented updated research report on ‘Whole Genome Sequencing Market’, offering insightful information like market share, market size, and growth rate during the ...
- Next Generation Sequencing Market Size, Growth Research Analysis, Outlook and Share to be worth more than $ 16.6 Bn by 2025on November 12, 2020 at 8:08 am
Targeted Re-Sequencing, and Whole Genome Sequencing. In terms of technology, re-sequencing and targeted sequencing amassed a huge share of the global market. The targeted sequencing decreases ...
- Molecular epidemiologist tracks virus with genome sequencing and comparative phylogenetic analysison November 6, 2020 at 8:41 am
In a new project, Lee is working on developing rapid, low-cost, automated whole-genome sequencing for emerging pathogens. This technique would provide information about similar viruses ...
- Parents, MDs agree: genome sequencing as first-tier diagnostic benefits infants in ICUon November 5, 2020 at 8:18 am
Two dozen of those babies were too seriously ill to be randomized and instead received ultra-rapid whole genome sequencing to return results to attending physicians as soon as possible—a median ...
- Molecular epidemiologist tracks virus with genome sequencing and comparative phylogenetic analysison November 5, 2020 at 7:13 am
In a new project, Lee is working on developing rapid, low-cost, automated whole-genome sequencing for emerging pathogens. This technique would provide information about similar viruses, patterns of ...
via Bing News